Doximity Inc (DOCS)vsMerck & Company Inc (MRK)
DOCS
Doximity Inc
$24.20
-1.51%
HEALTHCARE · Cap: $4.56B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 10093% more annual revenue ($65.01B vs $637.78M). DOCS leads profitability with a 37.5% profit margin vs 28.1%. DOCS appears more attractively valued with a PEG of 0.67. DOCS earns a higher WallStSmart Score of 66/100 (B-).
DOCS
Strong Buy66
out of 100
Grade: B-
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+45.2%
Fair Value
$47.37
Current Price
$24.20
$23.17 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 38 of every $100 in revenue as profit
Strong operational efficiency at 38.9%
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Earnings declined 16.2%
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : DOCS
The strongest argument for DOCS centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 37.5% and operating margin at 38.9%. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : DOCS
The primary concerns for DOCS are EPS Growth.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
DOCS profiles as a mature stock while MRK is a value play — different risk/reward profiles.
DOCS carries more volatility with a beta of 1.42 — expect wider price swings.
DOCS is growing revenue faster at 9.8% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
DOCS scores higher overall (66/100 vs 59/100), backed by strong 37.5% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Doximity Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians. Headquartered in San Francisco, California, Doximity’s Class A common stock trades on the New York Stock Exchange under the ticker DOCS.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?